Recent investigations on retatrutide, a dual activator for glucagon-like peptide-1 and gastric inhibitory polypeptide, indicate encouraging findings in addressing excess body fat and type 2 diabetes. Early information from clinical assessments show substantial reductions in body mass and bettered